Literature DB >> 16287602

Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects.

Roman Huber1, M Rostock, R Goedl, R Lüdtke, K Urech, S Buck, R Klein.   

Abstract

OBJECTIVE: Various immunological effects have been reported during application of mistletoe preparations. Because these data are heterogeneous, we performed a placebo controlled study to investigate (1) effects on peripheral granulocyte and eosinophil counts, (2) related cytokine levels and (3) whether effects are related to mistletoe lectin (ML).
METHODS: 43 volunteers were randomized to receive the mistletoe plant extract Iscador Quercus spezial (IQ), purified ML, IQ which was depleted from ML, or placebo subcutaneously twice per week for 8 weeks. Weekly, differential blood count and every four weeks spontaneous and IQ- and ML-induced cytokine production by peripheral blood mononuclear cells (PBMC) were analyzed.
RESULTS: Leukocyte-, granulocyte-, and eosinophil counts were significantly higher during treatment in the IQ- and ML-groups than in the placebo group. Furthermore, a significant increase of antigen-induced production of GM-CSF, IL-5 and IFNgamma by PBMC was observed in the IQ- and ML-group but not in the groups receiving ML-depleted IQ or placebo. Severe side effects did not occur in any of the subjects.
CONCLUSIONS: Treatment with IQ or ML stimulates the production of GM-CSF, IL-5 and IFNgamma by PBMC, and this is accompanied by an increase of eosinophil- and granulocyte-counts. These observations may, therefore, open rational therapeutic indications for mistletoe extracts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16287602

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  15 in total

1.  Pharmacokinetics of natural mistletoe lectins after subcutaneous injection.

Authors:  Roman Huber; Jürgen Eisenbraun; Barbara Miletzki; Michael Adler; Rainer Scheer; Reinhild Klein; Christoph H Gleiter
Journal:  Eur J Clin Pharmacol       Date:  2010-05-14       Impact factor: 2.953

2.  A new development of triterpene acid-containing extracts from Viscum album L. displays synergistic induction of apoptosis in acute lymphoblastic leukaemia.

Authors:  C I Delebinski; S Jaeger; K Kemnitz-Hassanin; G Henze; H N Lode; G J Seifert
Journal:  Cell Prolif       Date:  2012-01-03       Impact factor: 6.831

Review 3.  Mistletoe therapy in oncology.

Authors:  M A Horneber; G Bueschel; R Huber; K Linde; M Rostock
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

4.  Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells.

Authors:  Soo Jung Lee; Young-Ok Son; Hyunjin Kim; Joo-Young Kim; Soon-Won Park; Jae-Ho Bae; Hyung Hoi Kim; Eun-Yup Lee; Byung-Seon Chung; Sun-Hee Kim; Chi-Dug Kang
Journal:  J Clin Immunol       Date:  2007-05-25       Impact factor: 8.317

5.  Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects.

Authors:  Roman Huber; Holger Lüdtke; Johannes Wieber; Christiane Beckmann
Journal:  BMC Complement Altern Med       Date:  2011-11-24       Impact factor: 3.659

6.  Impact of Mistletoe Triterpene Acids on the Uptake of Mistletoe Lectin by Cultured Tumor Cells.

Authors:  Katharina Mulsow; Thomas Enzlein; Catharina Delebinski; Sebastian Jaeger; Georg Seifert; Matthias F Melzig
Journal:  PLoS One       Date:  2016-04-18       Impact factor: 3.240

7.  Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model.

Authors:  Carmen Steinborn; Amy Marisa Klemd; Ann-Sophie Sanchez-Campillo; Sophie Rieger; Marieke Scheffen; Barbara Sauer; Manuel Garcia-Käufer; Konrad Urech; Marie Follo; Annekathrin Ücker; Gunver Sophia Kienle; Roman Huber; Carsten Gründemann
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

8.  Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo.

Authors:  Christian M Strüh; Sebastian Jäger; Astrid Kersten; Christoph M Schempp; Armin Scheffler; Stefan F Martin
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

9.  Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study.

Authors:  Kab-Choong Kim; Jeong-Hwan Yook; Jürgen Eisenbraun; Byung-Sik Kim; Roman Huber
Journal:  BMC Complement Altern Med       Date:  2012-10-03       Impact factor: 3.659

10.  Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials?

Authors:  Renatus Ziegler
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-04       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.